In This Issue
Treating DCIS with APBI
Research Shows Favorable Results with SAVI
Experts Say JAMA Study is Misleading
BrachyBytes Editorial Advisory Board

Deanna Attai, M.D.
Robert Kuske, M.D.
Jay Reiff, Ph.D.
Dan Scanderbeg, Ph.D.
Catheryn Yashar, M.D.
Vic Zannis, M.D.

Upcoming Events

BC3 Conference
July 19-21, 2012
JW Marriott Washington, D.C.
Washington, D.C.

Become a Center of Excellence in APBI
Click here to learn about becoming a Center of Excellence and find ways to grow your APBI program by reaching out to referring physicians and women in the community.


Contact for more information.
Follow-up Links

Past Issues
Cianna Medical
SAVI Sisters

UC San Diego Moores Cancer Center

World Congress of Brachytherapy
American Society of Breast Surgeons
American Brachytherapy Society
American Society of Breast Disease

May 2012

Treating DCIS with APBI: The Debate Continues 

John Einck, MD & Kerri Perry, MD, FACS

The use of accelerated partial breast radiation (ABPI) as part of breast conservation therapy for patients with ductal carcinoma in situ (DCIS) has been an ongoing controversy in the treatment of early-stage breast cancer.   John Einck, MD

According to a new study presented at the recent meeting of the American Society of Breast Surgeons (ASBrS), APBI appears to be an effective treatment for patients with DCIS, resulting in favorably low rates of recurrence and toxicity. Researchers reported on 265 Kerri Perry, MD, FACSpatients, making it the largest study of DCIS patients treated with APBI to date.

Lead author and radiation oncologist John Einck, MD, and co-author and breast surgeon Kerri Perry, MD, FACS, discuss their views on the controversial subject, including what the results of their groundbreaking study mean for the future of DCIS treatment.

Read more


Do you offer APBI to eligible patients with DCIS, or do you think more long-term data is required? Email us to share your thoughts on the topic.

Research Shows Favorable Results with SAVI Breast Brachytherapy 

Physicians from the SAVI Collaborative Research Group presented data demonstrating favorable results with strut-based brachytherapy at two recent medical conferences.

According to a groundbreaking study presented at the 13th annual meeting of the American Society of Breast Surgeons, breast brachytherapy with SAVI appears to be an effective treatment for women with DCIS. The study, which is the largest ever presented on the use of APBI to treat DCIS, demonstrated favorably low rates of recurrence and toxicity. Read more

At the 2012 World Congress of Brachytherapy, researchers presented four-year data on the SAVI applicator. The poster concluded that SAVI is a well-tolerated and effective treatment for early-stage breast cancer, resulting in favorably low recurrence rates and minimal acute and late toxicities. Read more

SAVI Breast Brachytherapy Research - Robert Kuske, MD - Arizona Breast Cancer Specialists
Robert Kuske, MD, discusses SAVI research presented at ASBrS.

Experts Say JAMA Study is Misleading 
The Journal of the American Medical Association (JAMA) published a study in its May 2 issue comparing complication rates of breast brachytherapy vs. whole breast irradiation. This is similar to the data presented at the 2011 San Antonio Breast Cancer Symposium in December. Aunt Minnie: JAMA Paper Reignites Debate Over APBI

The study prompted an immediate response from many physicians and professional societies, who say it contains misleading information that may unnecessarily deter women from getting breast brachytherapy. Health Imaging: When Misinformation Metastasizes  

  • The American Society of Breast Surgeons published data from its MammoSite Registry Trial showing that brachytherapy is equally effective – if not more effective – in preventing local breast cancer recurrence than WBI, noting that the results directly contradict those of the JAMA study. Read more
  • The American Brachytherapy Society expressed its views on the JAMA study’s many flaws, saying “statements that disparage the use of breast brachytherapy based on the data presented in this study are therefore without merit and irresponsible.” Read more
  • The American Society of Breast Disease issued a statement expressing its concern regarding the study, stating that “brachytherapy remains a valuable method of treatment for appropriately selected patients, and that it should continue to be offered to appropriate women as a treatment choice.” Read more


What are your thoughts on the recent study published in JAMA? Has it affected your decision to offer APBI as a treatment option to eligible patients? Email us to share your opinion.